Literature DB >> 1331021

Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.

C A Kruse1, D H Mitchell, B K Kleinschmidt-DeMasters, W A Franklin, H G Morse, E B Spector, K O Lillehei.   

Abstract

The establishment of a new glioma cell line, DBTRG-05MG, in a modified RPMI 1640 medium is described. The cells were derived from an adult female with glioblastoma multiforme who had been treated with local brain irradiation and multidrug chemotherapy; the tumor showed substantial change in histologic appearance compared to the original biopsy 13 mo. previously. The line has been successfully cryopreserved and passaged up to 20 times. The karyotype of the cells demonstrated it as a hypotetraploid line; the DNA index of 1.9 confirmed the karyotype analyses. By immunocytochemical analysis, the cell line reacted with polyclonal antibodies to vimentin, S100, and neuron specific enolase, reflecting its primitive neuroectodermal character. Positive immunostaining for epidermal growth factor receptor correlated with the excess of chromosome 7 seen in the karyotype. The cell line reacted negatively to antibodies against platelet-derived growth factor and its receptor, neuronal cell adhesion molecule, and glial fibrillary acidic protein. By flow cytometry, the cells were major histocompatibility class I antigen positive and class I antigen negative. Growth kinetic studies demonstrated an approximate population doubling time of 34 to 41 h and a colony forming efficiency of 71.4%. Western blot analysis showed the presence of low levels of normal-sized retinoblastoma protein. When compared to the patient's lymphocyte DNA, no loss of heterozygosity of the p53 tumor suppressor gene was observed in the DBTRG-05MG cell line DNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331021     DOI: 10.1007/bf02631035

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  24 in total

1.  Characteristics of an established human glioma cell line, KNS-42.

Authors:  I Takeshita; T Takaki; M Kuramitsu; S Nagasaka; T Machi; H Ogawa; H Egami; H Mannoji; M Fukui; K Kitamura
Journal:  Neurol Med Chir (Tokyo)       Date:  1987-07       Impact factor: 1.742

2.  Amplification of a highly polymorphic VNTR segment by the polymerase chain reaction.

Authors:  G T Horn; B Richards; K W Klinger
Journal:  Nucleic Acids Res       Date:  1989-03-11       Impact factor: 16.971

3.  Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines.

Authors:  W Henn; N Blin; K D Zang
Journal:  Hum Genet       Date:  1986-09       Impact factor: 4.132

Review 4.  Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes.

Authors:  L F Eng
Journal:  J Neuroimmunol       Date:  1985-06       Impact factor: 3.478

5.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

6.  Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens.

Authors:  B de Muralt; N de Tribolet; A C Diserens; D Stavrou; J P Mach; S Carrel
Journal:  Eur J Cancer Clin Oncol       Date:  1985-02

7.  Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice.

Authors:  S C Schold; D E Bullard; S H Bigner; T R Jones; D D Bigner
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas.

Authors:  H J Xu; S X Hu; P T Cagle; G E Moore; W F Benedict
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

9.  Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines.

Authors:  M Nistér; T A Libermann; C Betsholtz; M Pettersson; L Claesson-Welsh; C H Heldin; J Schlessinger; B Westermark
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

10.  Characterization of four human malignant glioma cell lines.

Authors:  A Studer; N de Tribolet; A C Diserens; A C Gaide; J M Matthieu; S Carrel; D Stavrou
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

View more
  25 in total

1.  Improved technique for establishing short term human brain tumor cultures.

Authors:  M A Farr-Jones; I F Parney; K C Petruk
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.

Authors:  Jiang-bo Tang; David Svilar; Ram N Trivedi; Xiao-hong Wang; Eva M Goellner; Briana Moore; Ronald L Hamilton; Lauren A Banze; Ashley R Brown; Robert W Sobol
Journal:  Neuro Oncol       Date:  2011-03-03       Impact factor: 12.300

3.  The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.

Authors:  Grace Huang; Baotran Ho; Jeffrey Conroy; Song Liu; Hu Qiang; Vita Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

4.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

Authors:  C A Kruse; P M Schiltz; D Bellgrau; Q Kong; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

6.  Isolation, preliminary characterization, and full-genome analyses of tick-borne encephalitis virus from Mongolia.

Authors:  Stefan Frey; Ilona Mossbrugger; Damdin Altantuul; Jigjav Battsetseg; Rendoo Davaadorj; Damdindorj Tserennorov; Tsoodol Buyanjargal; Dashdavaa Otgonbaatar; Lothar Zöller; Stephanie Speck; Roman Wölfel; Gerhard Dobler; Sandra Essbauer
Journal:  Virus Genes       Date:  2012-07-31       Impact factor: 2.332

7.  Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Authors:  Vita M Golubovskaya; Grace Huang; Baotran Ho; Michael Yemma; Carl D Morrison; Jisook Lee; Brian P Eliceiri; William G Cance
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

8.  Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.

Authors:  Alessandra De Robertis; Silvia Valensin; Marco Rossi; Patrizia Tunici; Margherita Verani; Antonella De Rosa; Cinzia Giordano; Maurizio Varrone; Arianna Nencini; Carmela Pratelli; Tiziana Benicchi; Annette Bakker; Jeffrey Hill; Kanda Sangthongpitag; Vishal Pendharkar; Boping Liu; Fui Mee Ng; Siew Wen Then; Shi Jing Tai; Seong-Moon Cheong; Xi He; Andrea Caricasole; Massimiliano Salerno
Journal:  Mol Cancer Ther       Date:  2013-04-25       Impact factor: 6.261

9.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

Review 10.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.